AstraZeneca is a global science‑led patient‑focused biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines for some of the world’s most serious diseases. We are more than one of the world’s leading pharmaceutical companies.

AstraZeneca is accelerating the expansion of our geographical footprint in rare diseases following the acquisition of Alexion in 2021. Rare diseases is a high‑growth therapy area with rapid innovation and significant unmet medical need. Over 7,000 rare diseases are known today yet less than 1% of them have an approved treatment.

The Rare Disease Medical Partner (RDMP) is a senior field‑based scientific and strategic leader responsible for driving medical excellence and shaping the rare disease ecosystem in alignment with AstraZeneca’s vision of pioneering innovation for patients with high unmet needs.

Building on the foundations of...